Clinical trial
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
NCT00977574 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- September 14, 2009
- Completion date
- March 6, 2027
- Enrollment
- 349 (actual)
- Sites
- 230
Conditions
As the registry lists them; a condition with its own page is linked.
endometrial adenocarcinoma, endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma, recurrent malignant uterine corpus neoplasm, stage iiia uterine corpus carcinoma or carcinosarcoma by ajcc v7 stage, stage iiib uterine corpus carcinoma or carcinosarcoma by ajcc v7 stage, stage iiic uterine corpus carcinoma or carcinosarcoma by ajcc v7 stage, stage iva uterine corpus carcinoma or carcinosarcoma by ajcc v7 stage, stage ivb uterine corpus carcinoma or carcinosarcoma by ajcc v7 stage